| Verifiedfields: | changed |
| Watchedfields: | changed |
| Verifiedrevid: | 458283869 |
| Type: | mab |
| Mab Type: | scFv |
| Source: | zu |
| Target: | EpCAM |
| Atc Prefix: | L01 |
| Atc Suffix: | FX16 |
| Chemspiderid: | none |
| Cas Number: | 945228-48-8 |
| Unii: | 945CY7ZMI2 |
| Drugbank: | DB05319 |
| Kegg: | D11913 |
| Synonyms: | oportuzumab monatox-qqrs |
| C: | 3072 |
| H: | 4723 |
| N: | 877 |
| O: | 952 |
| S: | 12 |
Oportuzumab monatox is an experimental anti-cancer medication. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the medication's name).[1]
The drug was developed by Canadian-based Viventia Bio Inc. The company was acquired by Cambridge(MA)-based Eleven Biotherapeutics in 2016, which then changed its name to Sesen Bio.[2] In 2019 Sesen Bio reported updated, preliminary primary and secondary endpoint data from the company's Phase 3 VISTA trial further supporting the strong benefit-risk profile of Vicineum for the potential treatment of patients with high-risk, bacillus Calmette-Guérin(BCG) unresponsive, non-muscle invasive bladder cancer (NMIBC).[3] The Company applied for approval of Vicineum by the United States Food and Drug Administration and the European Medicines Agency.
Vol 24, No 18S (June 20 Supplement), 2006: 4580